During the last session, Altimmune Inc. (NASDAQ:ALT)’s traded shares were 1.99 million, with the beta value of the company hitting 0.91. At the end of the trading day, the stock’s price was $10.60, reflecting an intraday gain of 12.29% or $1.16. The 52-week high for the ALT share is $17.26, that puts it down -62.83 from that peak though still a striking 63.87% gain since the share price plummeted to a 52-week low of $3.83. The company’s market capitalization is $372.80M, and the average trade volume was 1.04 million shares over the past three months.
Altimmune Inc. (ALT) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. ALT has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.61.
Altimmune Inc. (NASDAQ:ALT) trade information
Altimmune Inc. (ALT) registered a 12.29% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.29% in intraday trading to $10.60 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 27.40%, and it has moved by 118.56% in 30 days. Based on these gigs, the overall price performance for the year is -34.53%.
The consensus price target of analysts on Wall Street is $23.14, which implies an increase of 54.19% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $30.00 respectively. As a result, ALT is trading at a discount of -183.02% off the target high and -13.21% off the low.
Altimmune Inc. (ALT) estimates and forecasts
Statistics show that Altimmune Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Altimmune Inc. (ALT) shares have gone up 14.97% during the last six months, with a year-to-date growth rate less than the industry average at 8.21% against 11.30. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -1.70% this quarter and then jump 21.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -8.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.01 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $1 million by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 45.70%. While earnings are projected to return -22.90% in 2022.
Altimmune Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Altimmune Inc. (NASDAQ:ALT)’s Major holders
Altimmune Inc. insiders own 5.46% of total outstanding shares while institutional holders control 69.37%, with the float percentage being 73.38%. State Street Corporation is the largest shareholder of the company, while 144 institutions own stock in it. As of Dec 30, 2021, the company held over 4.42 million shares (or 10.23% of all shares), a total value of $40.5 million in shares.
The next largest institutional holding, with 2.94 million shares, is of Blackrock Inc.’s that is approximately 6.79% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $17.88 million.
Also, the Mutual Funds coming in first place with the largest holdings of Altimmune Inc. (ALT) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and College Retirement Equities Fund-Stock Account. Data provided on Jan 30, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 4.25 million shares. This amounts to just over 9.83 percent of the company’s overall shares, with a $34.27 million market value. The same data shows that the other fund manager holds slightly less at 1.13 million, or about 2.60% of the stock, which is worth about $10.31 million.